YHLO Joined Hands With Peking University In Molecular Diagnosis
Recently, YHLO has signed an agreement with Peking University (one of the historic and prestigious universities worldwide) to establish a collaborative laboratory for molecular diagnosis of infectious diseases to carry out R&D in the field of liver diseases diagnostics. This significant cooperation with Peking University will leverage the advantages of its medical disciplines and talents to conduct researches on molecular diagnosis of infectious diseases, which focuses on the latest technologies and innovative products in the IVD industry, which will make the joint lab an international advanced technology research and industrialization base.
At present, viral hepatitis and emerging infectious diseases are still the critical harms to public health problems in the world. WHO has advocated that the goal of eliminating viral hepatitis as of 2030 worldwide. Thus, corresponding plans and measures have been formulated one after another. However, screening of patients with viral hepatitis becomes a big challenge, in which hepatitis B and C are the most common causes of death, resulting in the loss of 1.4 million lives each year. During the prevalence of COVID-19 pandemic, viral hepatitis still kills thousands of people every day. If it is not diagnosed and treated in time, some of them will evolve to liver cirrhosis and liver cancer, seriously influences the quality of patients’ daily life and brings a great family and social burden.
However, due to the reasons of unawareness, low screening coverage and asymptomatic in the early stage of viral hepatitis, many patients are diagnosed at the late stage of liver disease, while some may deteriorate into liver failure, cirrhosis or liver cancer when chronic hepatitis is diagnosed. Therefore, the screening of patients with viral hepatitis is extremely important, but there are still some limitations in current diagnostics methods such as there is still no breakthrough in the detection of specific indicators of hepatitis B. It is necessary to urge further investment to establish a corresponding diagnosis program and lay the foundation for the cure of hepatitis B. The aim of this laboratory is to create leading facilities and apply the novel technology in the battle of infectious virology.
The school representative of Peking University said: “YHLO is a rather innovative IVD enterprise in China. Together with YHLO, we hope to attract outstanding talents globally to build a first-class research platform of in vitro diagnosis, that will lead the developing way of molecular diagnosis in infectious disease.” said the representative of Peking University.
Michael Hu, chairman of YHLO said, “As one of the top universities in China, Peking University has cultivated many top talents in various fields. We have been looking forward to cooperating with the experts in the field from PKU. Since the Peking University - YHLO Joint Laboratory was established, we will build an open cooperation platform for in vitro diagnosis industry that would enhance the capability of technological innovation, speed up the rate of technology transfer and process of product industrialization.” YHLO will continue to provide reliable, high-quality innovations in healthcare and services worldwide to improve human well-being.
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
